Table 1 Main characteristics of studies included
Author | Year | Country | MA (year) | TNM stage | Time of diagnosis | MF (months) | Sample size | Sequencing methods | Mut: WT | Survival endpoints | HR(e) | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sarshekeh | 2017 | US | 52 | II–IV | 2000–2014 | 50 | 734 | HiSeq | 90:644 | OS; PFS | HR | 9 |
Mizuno | 2018 | US | 56 | IV | 2005–2015 | 22 | 237 | NGS | 31:206 | OS RFS | HR Curve | 9 |
Oyanagi | 2019 | Japan | NR | I–IV | 2009–2015 | NR | 201 | NGS | 56:145 | OS | Curve | 7 |
Liao | 2019 | China | NR | I–IV | 2013–2017 | NR | 84 | NGS | 1:2 | NR | NR | 8 |
Fleming | 2013 | Australia | 69 | I–IV | NR | NR | 744 | Applied Biosystems | 64:680 | NR | NR | 6 |
Stahler | 2020 | Germany | NR | IV | 2007–2012 | 40·3 | 373 | NGS | NR | OS; PFS | HR | 8 |
Jia | 2017 | US | NR | NR | NR | NR | 53 | NR | 4:49 | NR | NR | 6 |
Ando | 2005 | Japan | 66 | A–Da | NR | NR | 30 | NR | 1:29 | NR | NR | 7 |
Miyaki | 1999 | Japan | NR | NR | NR | NR | 61 | NR | 9:52 | NR | NR | 6 |
Khan | 2018 | US | NR | NR | 2012–2016 | 51.6 | 1877 | NGS | 226:1599 | OS | HR | 7 |